Centessa Pharmaceuticals Plc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Centessa Pharmaceuticals Plc (CNTA) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Centessa Pharmaceuticals Plc vs Its Competitors
- Structure: Centessa Pharmaceuticals Plc operates in the following segments: Reportable.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
API endpoints for this dataset
Centessa Pharmaceuticals Plc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Centessa Pharmaceuticals Plc | - | - | - | Yes |
| Competitors combined (74) | ||||
| High-Confidence Competitors (7) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CNTA Stock Performance relative to its Competitors
CNTA Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Moderna Inc | 282.9% | Outperformed |
| 2 | Damora Therapeutics Inc | 282.9% | Outperformed |
| 3 | An2 Therapeutics Inc | 282.9% | Outperformed |
| 4 | Prelude Therapeutics Inc | 282.9% | Outperformed |
| 5 | Edgewise Therapeutics inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Centessa Pharmaceuticals Plc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Centessa Pharmaceuticals Plc's Comment on Competition and Industry Peers
Publicly Traded Peers of Centessa Pharmaceuticals Plc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Centessa Pharmaceuticals Plc |
6,218.76 | - |
 Beone Medicines Ltd |
612,622.08 | 6,128.24 |
 Amgen Inc |
250,468.48 | 38,095.00 |
 Pfizer Inc |
169,021.89 | 63,625.00 |
 Vertex Pharmaceuticals Inc |
139,617.37 | 12,951.60 |
 Bristol myers Squibb Company |
127,573.42 | 50,033.00 |
| SUBTOTAL | 1,781,789.00 | 243,978.31 |
Sign in to see all competitors of Centessa Pharmaceuticals Plc.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Centessa Pharmaceuticals Plc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Centessa Pharmaceuticals Plc's Competitors Named by the Company
Competitive relationships identified from Centessa Pharmaceuticals Plc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Takeda Pharmaceuticals Company Limited | Company report | 85% |
| Alkermes plc | Company report | 85% |
| Merck & Co., Inc. | Company report | 85% |
| Keros Therapeutics, Inc. | Company report | 85% |
| AstraZeneca | Company report | 85% |
| Horizon Therapeutics plc | Company report | 85% |
| Biogen | Company report | 85% |
| CERC-002 | Company report | 85% |
Company report basis, confidence, active dates and source counts for Centessa Pharmaceuticals Plc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Centessa Pharmaceuticals Plc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Centessa Pharmaceuticals Plc | Reportable 100.00 % |
| Amgen Inc | Reportable 100.00 % |
| Pfizer Inc | U.S. Commercial Division 58.35 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Teva Pharmaceutical Industries Limited | United States 42.55 % |
| Illumina Inc | Sequencing 90.43 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Centessa Pharmaceuticals Plc.
Centessa Pharmaceuticals Plc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Centessa Pharmaceuticals Plc | 6,219 | - | -2,124,051 |
| Beone Medicines Ltd | 612,622 | 510,686 | 54,642 |
| Amgen Inc | 250,468 | 2,930,385 | 672,538 |
| Pfizer Inc | 169,022 | 848,333 | 54,160 |
| Vertex Pharmaceuticals Inc | 139,617 | 31,979,259 | 9,817,037 |
| Bristol myers Squibb Company | 127,573 | 1,539,477 | 284,338 |
| PEERS TOTAL | 1,775,570 | 995,269 | 96,869 |
Sign in to see all peers for Centessa Pharmaceuticals Plc.
Centessa Pharmaceuticals Plc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Beone Medicines Ltd | United States 54.39 % |
| Pfizer Inc | United States 63.93 % |
| Vertex Pharmaceuticals Inc | United States 63.04 % |
| Bristol myers Squibb Company | United States 69.43 % |
| Teva Pharmaceutical Industries Limited | Europe 30.49 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Centessa Pharmaceuticals Plc.
Centessa Pharmaceuticals Plc's Position in Industry Market Structure
Market-capitalization share and concentration across all 495 companies in Centessa Pharmaceuticals Plc's industry classification, broader than the peer set above. Market cap in millions of $.Centessa Pharmaceuticals Plc ranks #0 of 495 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 875, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,210,070 | 20.69 % |
| 2 | Johnson and Johnson | 674,004 | 11.53 % |
| 3 | Beone Medicines Ltd | 612,622 | 10.48 % |
| 4 | Abbvie Inc | 515,910 | 8.82 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 1,234 | 5.2% |
| 0 | Centessa Pharmaceuticals Plc | 6,219 | 0.00 % |
Market cap and industry share for the rest of Centessa Pharmaceuticals Plc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-06-29.
Centessa Pharmaceuticals Plc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (444 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.6x | - |
| EV / EBITDA | - | 15.9x | - |
| P/B | 9.5x | 4.3x | +5.2x |
| Return on Equity | -60.37 % | industry aggregate | -77.18 % |
| Return on Invested Capital | -26.86 % | -9.83 % (avg) | -17.03 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Centessa Pharmaceuticals Plc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - |
| Operating Margin | - | - | - | - | - |
| Return on Invested Capital | - | -24.27 % | -27.83 % | -25.31 % | -22.94 % |
| P/E | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Centessa Pharmaceuticals Plc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 875 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Centessa Pharmaceuticals Plc's dedicated Suppliers and Customers pages, not here.
Centessa Pharmaceuticals Plc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Return on equity 77.2 points below the industry aggregate.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (48.60 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-7.5% annualized).
Methodology: see Methodology: SWOT Analysis.
Centessa Pharmaceuticals Plc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Centessa Pharmaceuticals Plc | 1.58 | 9.58 | 0.26 |
| Beone Medicines Ltd | 2.30 | 3.16 | 0.23 |
| Amgen Inc | 0.46 | 1.26 | 5.86 |
| Pfizer Inc | 0.04 | 1.27 | 0.72 |
| Vertex Pharmaceuticals Inc | 1.30 | 2.83 | 0.06 |
| Bristol myers Squibb Company | 0.48 | 1.44 | 2.12 |
Sign in to see all peers for Centessa Pharmaceuticals Plc.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Centessa Pharmaceuticals Plc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Centessa Pharmaceuticals Plc | Q1 2026 | - | - |
| Beone Medicines Ltd | Q2 2026 | +29.7 % | +151.3 % |
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| Pfizer Inc | Q3 2026 | -0.4 % | -8.7 % |
| Vertex Pharmaceuticals Inc | Q3 2026 | +11.8 % | -39.6 % |
| Bristol myers Squibb Company | Q3 2026 | +6.9 % | -1.5 % |
| PEERS TOTAL | +8.6 % | +27.5 % |
Sign in to see all peers for Centessa Pharmaceuticals Plc.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Centessa Pharmaceuticals Plc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Centessa Pharmaceuticals Plc | Q1 2026 | - | - |
| Beone Medicines Ltd | Q2 2026 | +6.4 % | -57.0 % |
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
| Pfizer Inc | Q3 2026 | -3.5 % | -4.8 % |
| Vertex Pharmaceuticals Inc | Q3 2026 | +26.8 % | -4.4 % |
| Bristol myers Squibb Company | Q3 2026 | +20.7 % | +7.5 % |
Sign in to see all peers for Centessa Pharmaceuticals Plc.
Centessa Pharmaceuticals Plc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Centessa Pharmaceuticals Plc | - | - | - |
| Beone Medicines Ltd | 7.82% | 10.32% | 14.24% |
| Amgen Inc | 9.48% | 13.08% | 89.32% |
| Pfizer Inc | 1.98% | 2.34% | 4.62% |
| Vertex Pharmaceuticals Inc | 14.16% | 16.63% | 20.08% |
| Bristol myers Squibb Company | 10.47% | 13.59% | 43.83% |
Sign in to see all peers for Centessa Pharmaceuticals Plc.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Centessa Pharmaceuticals Plc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Centessa Pharmaceuticals Plc | - | - |
| Beone Medicines Ltd | 924.91 | 99.97 |
| Amgen Inc | 28.60 | 6.57 |
| Pfizer Inc | 41.83 | 2.66 |
| Vertex Pharmaceuticals Inc | 35.27 | 10.78 |
| Bristol myers Squibb Company | 13.77 | 2.55 |
| PEERS AVERAGE | 75.83 | 7.30 |
Sign in to see all peers for Centessa Pharmaceuticals Plc.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.